Display options
Cite
Quattrocchi CC, Dell'Aia P, Errante Y, et al. Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. J Bone Oncol. 2012;1(1):24-9doi: 10.1016/j.jbo.2012.02.001.
Quattrocchi, C. C., Dell'Aia, P., Errante, Y., Occhicone, F., Longo, D., Virzì, V., Tonini, G., Napoli, N., Santini, D., & Beomonte Zobel, B. (2012). Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. Journal of bone oncology, 1(1), 24-9. https://doi.org/10.1016/j.jbo.2012.02.001
Quattrocchi, Carlo C, et al. "Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases." Journal of bone oncology vol. 1,1 (2012): 24-9. doi: https://doi.org/10.1016/j.jbo.2012.02.001
Quattrocchi CC, Dell'Aia P, Errante Y, Occhicone F, Longo D, Virzì V, Tonini G, Napoli N, Santini D, Beomonte Zobel B. Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. J Bone Oncol. 2012 Mar 23;1(1):24-9. doi: 10.1016/j.jbo.2012.02.001. eCollection 2012 Jun. PMID: 26909251; PMCID: PMC4723329.
Copy Download .nbib Format: NLM
Share it on

J Bone Oncol. 2012 Mar 23;1(1):24-9. doi: 10.1016/j.jbo.2012.02.001. eCollection 2012 Jun.

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases.

Journal of bone oncology

Carlo C Quattrocchi, Paola Dell'Aia, Yuri Errante, Filomena Occhicone, Daniela Longo, Vladimir Virzì, Giuseppe Tonini, Nicola Napoli, Daniele Santini, Bruno Beomonte Zobel

Affiliations

  1. Radiology at University Campus Bio-Medico of Rome, via Alvaro del Portillo, 21, Rome 00128, Italy.
  2. IRCCS Ospedale Pediatrico Bambino Gesù, Radiology, Piazza Sant'Onofrio, 4, Rome 00100, Italy.
  3. Oncology at University Campus Bio-Medico of Rome, via Alvaro del Portillo, 21, Rome 00128, Italy.
  4. Endocrinology at University Campus Bio-Medico of Rome, via Alvaro del Portillo, 21, Rome 00128, Italy.

PMID: 26909251 PMCID: PMC4723329 DOI: 10.1016/j.jbo.2012.02.001

Abstract

PURPOSE: To evaluate bone density changes at the level of normal bone and bone metastases after zoledronic acid (ZA) treatment in oncologic patients.

MATERIALS AND METHODS: We retrospectively evaluated 72 consecutive adult patients with histologically confirmed solid tumors with at least 1 newly diagnosed bone metastatic lesion. Bone metastases were diagnosed by bone scans and confirmed with computed tomography (CT). Patients received intravenous ZA, 4 mg, by 15-min infusion every 28 day through a peripheral or a central venous access and were monitored for at least 3 months and a maximum of 24 months. Bone density was determined at the level of bone metastases and at the level of normal trabecular and cortical bone using a ROI-based approach.

RESULTS: A significant increase was demonstrated at the level of normal trabecular bone of the calvarium and the femoral neck. No significant increase of density was observed at the level of the normal cortical bone. Bone metastases showed a significant increase in CT density as compared to baseline up to 24 months after zoledronic acid.

CONCLUSION: We have found that long term treatment with ZA increases trabecular bone density in oncologic patients whereas normal cortical bone changes are not detectable.

Keywords: Bone metastasis; CT Density; Cortical bone; Osteolytic; Trabecular bone; Zoledronic acid

References

  1. Breast. 2003 Aug;12 Suppl 2:S37-44 - PubMed
  2. Radiol Med. 2007 Oct;112(7):1049-59 - PubMed
  3. Nat Rev Cancer. 2002 Aug;2(8):584-93 - PubMed
  4. Radiother Oncol. 2004 Mar;70(3):291-4 - PubMed
  5. Lancet. 1992 Oct 31;340(8827):1049-52 - PubMed
  6. J Orthop Res. 2004 Nov;22(6):1161-7 - PubMed
  7. Am J Clin Oncol. 2005 Feb;28(1):8-16 - PubMed
  8. N Engl J Med. 2007 May 3;356(18):1809-22 - PubMed
  9. Cancer. 2004 Jan 1;100(1):36-43 - PubMed
  10. Jpn J Clin Oncol. 2005 Jan;35(1):28-33 - PubMed
  11. Cancer Invest. 1999;17(8):566-74 - PubMed
  12. J Clin Oncol. 1993 Jan;11(1):59-65 - PubMed
  13. J Clin Rheumatol. 2008 Oct;14(5):299-305 - PubMed
  14. N Engl J Med. 2004 Apr 15;350(16):1655-64 - PubMed
  15. J Clin Oncol. 2004 Jul 15;22(14):2942-53 - PubMed
  16. Br J Urol. 1991 Jul;68(1):74-80 - PubMed
  17. Transl Res. 2010 May;155(5):247-55 - PubMed
  18. J Clin Oncol. 2005 Aug 1;23(22):4925-35 - PubMed
  19. Cancer Res. 2002 Feb 1;62(3):917-23 - PubMed
  20. BJU Int. 2009 Feb;103(4):464-9 - PubMed
  21. Urology. 2007 Aug;70(2):315-9 - PubMed
  22. J Surg Oncol. 2008 Dec 1;98 (7):567-8 - PubMed
  23. Anat Rec. 1997 Dec;249(4):458-68 - PubMed
  24. BJU Int. 2005 Nov;96(7):964-9 - PubMed
  25. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69 - PubMed
  26. Clin Exp Metastasis. 2009;26(5):479-84 - PubMed
  27. Br J Cancer. 1994 Sep;70(3):554-8 - PubMed
  28. Am J Pathol. 2003 Nov;163(5):2021-31 - PubMed
  29. Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75 - PubMed
  30. N Engl J Med. 1996 Feb 22;334(8):488-93 - PubMed
  31. Br J Cancer. 1977 Mar;35(3):292-8 - PubMed
  32. Cancer. 2000 Jun 15;88(12 Suppl):3033-7 - PubMed
  33. J Clin Oncol. 2005 May 20;23(15):3314-21 - PubMed
  34. Cancer. 1997 Oct 15;80(8 Suppl):1546-56 - PubMed
  35. Can J Oncol. 1995 Dec;5 Suppl 1:16-27 - PubMed
  36. Skeletal Radiol. 2007 Dec;36(12 ):1121-7 - PubMed
  37. N Engl J Med. 1996 Dec 12;335(24):1785-91 - PubMed
  38. Skeletal Radiol. 1989;18(7):517-21 - PubMed
  39. Osteoporos Int. 2010 Jul;21(7):1277-85 - PubMed
  40. J Clin Oncol. 2006 Oct 20;24(30):4895-900 - PubMed
  41. BJU Int. 2009 Dec;104(11):1573-9 - PubMed
  42. J Clin Endocrinol Metab. 2007 Jan;92(1):131-6 - PubMed
  43. N Engl J Med. 2007 Nov 1;357(18):1799-809 - PubMed
  44. Br J Cancer. 2000 Feb;82(4):858-64 - PubMed

Publication Types